Microbiome-Host-Cancer Interface: A Narrative Review of Therapeutic Strategies, Current Challenges, and Global Opportunities
Trends in Medical Research · 10.10.2026 · 21 (1) · 87-100
DOI: 10.3923/tmr.2026.87.100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Medical Research, erschienen am 10.10.2026. Verfasst von Saheed Ayodeji Adekola und 4 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
Background and Objective:The human microbiome is critical in carcinogenesis and treatment outcomes.Here, we discuss microbiome-host interactions, synthesise clinical evidence on targeted interventions, and consider challenges in translation.It examines cost-effective, scalable microbiome strategies to advance oncology care in low-and middle-income countries (LMICs) with emphasis on biomarker discovery and standardisation of research.Materials and Methods: We performed a narrative search of PubMed, Scopus, and Web of Science to identify peer-reviewed studies published from January 2010 through April 2026.The screening was focused on cancer-microbiome host interactions, mechanisms, efficacy, safety, and applicability for global health.For this review, a total of 150 eligible studies, including preclinical models, observational studies and clinical trials, were critically analysed.
Results
The microbiome controls carcinogenesis through genotoxicity (e.g., colibactin from pks+ E. coli), chronic inflammation, T-cell priming and bioactive metabolites.In the clinic, faecal microbiota transplantation (FMT) and synbiotics improve anti-PD-1/PD-L1 response in refractory melanoma and reduce chemotherapy-induced mucositis and diarrhoea.Nevertheless, significant translational challenges include significant inter-individual heterogeneity, inconsistent strain engraftment, risk of opportunistic infection in immunocompromised patients and fractured regulatory frameworks.
Conclusion
Microbiome intervention improves efficacy and reduces toxicity of cancer therapies.In settings with limited resources, inexpensive prebiotics and probiotics can be easily added to oncology care.Prioritisation is needed for global clinical translation of biomarker discovery, standardisation of research protocols, and inclusion of LMIC populations in trials.
Zitieren
APA
Adekola, S. A., Igbayilola, Y. D., Oparinde, D. P., Aina, S. O., & Audu, N. M. (2026). Microbiome-Host-Cancer Interface: A Narrative Review of Therapeutic Strategies, Current Challenges, and Global Opportunities. Trends in Medical Research, 21(1), 87-100. https://doi.org/10.3923/tmr.2026.87.100
Vancouver
Adekola SA, Igbayilola YD, Oparinde DP, Aina SO, Audu NM. Microbiome-Host-Cancer Interface: A Narrative Review of Therapeutic Strategies, Current Challenges, and Global Opportunities. Trends in Medical Research. 2026;21(1):87-100. doi:10.3923/tmr.2026.87.100
BibTeX
@article{Adekola2026,
author = {Adekola, Saheed Ayodeji and Igbayilola, Yusuf Dimeji and Oparinde, Dolapo Pius and Aina, Samson Olawale and Audu, Ngabea Murtala},
title = {Microbiome-Host-Cancer Interface: A Narrative Review of Therapeutic Strategies, Current Challenges, and Global Opportunities},
journal = {Trends in Medical Research},
year = {2026},
volume = {21},
number = {1},
pages = {87--100},
doi = {10.3923/tmr.2026.87.100}
}
EUVIMED